Clinical trial
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel…
NCT00116142 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00116142 |
|---|---|
| Title | Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer |
| Official title | Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy |
| Enrollment | 350 |
| Start date | Jun 1, 2005 |
| Primary completion | Jun 29, 2020 |
| Completion | Jun 29, 2020 |
| First posted | Jun 28, 2005 |
| Last update posted | Jan 11, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: